Clinical Trial

Trans and Non-binary Prostate-Specific Antigen Reference Interval Determination Study

Study acronym: TransPRIDE
Recruiting
View on ClinicalTrials.gov →
Summary
The prostate specific antigen (PSA) blood test can help diagnose prostate problems, including cancer. The prostate is an organ in the pelvis. It is found in cisgender men, transgender (trans) women and some non-binary people. Anyone with a prostate can get prostate cancer. The prostate remains after genital (lower) surgery. The hormones and surgeries that trans women and non-binary people might have can lower the PSA. We do not have good data on the normal PSA levels are for this group TransPRIDE is a research study that will help us find the normal levels of PSA in trans women and non-binary people with prostates. Researchers will ask 500 trans women and non-binary people with prostates to take part. They will need to be aged 40 or over. They will need to be on hormones or have had lower surgery. They will be called after 6 months to recheck their health. If a person has a high PSA, they may be sent for more tests. Knowing the normal PSA level for trans women and non-binary people will help doctors to find and treat their prostate cancer more quickly.
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-05
Trial Details
NCT Number NCT06987045
Lead Sponsor Queen Mary University of London
Conditions Prostate CA
Enrollment 500 participants
Start Date 2026-04-04
Primary Completion 2028-03-31 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-04